20
Concord Biotech Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is CYCLOSPORINE USP, with a corresponding US DMF Number 23962.
Remarkably, this DMF maintains an Active status since its submission on July 08, 2010, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 05, 2013, and payment made on April 08, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II